⚕️ The information below is for educational purposes only. It is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.
Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Consult your healthcare provider before starting any medication or undergoing any laboratory tests.
Starting a GLP-1 receptor agonist — whether semaglutide (Ozempic, Wegovy, Rybelsus) or tirzepatide — is a significant medical decision. Yet in India, many patients begin these medications with incomplete baseline blood work, making it difficult to track whether the treatment is working or whether any side effects are developing silently.
This guide explains which tests to get, why each one matters, how much they cost at Indian labs, and what to do with the results.
When you start GLP-1 therapy, your body changes in measurable ways — blood sugar improves, lipid profiles shift, kidney function can be affected, and liver fat often decreases. Without a baseline measurement, you have no benchmark.
You cannot tell if semaglutide improved your HbA1c from 9.2% to 7.1% (an excellent result worth celebrating) or if your creatinine has silently risen (a potential warning sign) — because you did not measure it before starting.
Indian labs like Thyrocare, Dr Lal PathLabs, Metropolis, and Apollo Diagnostics offer most of these tests affordably, often bundled into preventive health packages. Getting a comprehensive baseline typically costs ₹1,500–₹4,000 depending on the city and lab.
Why: GLP-1 medications are prescribed for Type 2 diabetes (T2DM) and/or weight management. HbA1c gives a 3-month average of blood sugar control — the single most important marker for diabetic patients starting GLP-1 therapy.
What to expect: GLP-1 users with T2DM typically see HbA1c drop by 1.0–2.0 percentage points over 3–6 months of therapy.
Reference ranges:
Cost in India: ₹250–₹450 (standalone), cheaper in bundled packages
When to retest: At 3 months and again at 6 months after starting
Why: Provides an immediate snapshot of blood sugar control on the day of testing. GLP-1 medications work partly by stimulating insulin secretion in a glucose-dependent manner — you want to know where your fasting and post-meal glucose starts.
What to expect: Fasting blood glucose typically drops by 15–30 mg/dL in the first 8–12 weeks of semaglutide therapy.
Reference ranges (fasting):
Cost in India: ₹80–₹120 (FBG alone), ₹150–₹250 (both FBG and PPBG)
Why: GLP-1 medications consistently improve lipid profiles — reducing LDL cholesterol, VLDL, and triglycerides while modestly raising HDL. You need a baseline to quantify this benefit over time.
Includes: Total cholesterol, LDL (low-density lipoprotein), HDL (high-density lipoprotein), VLDL, and triglycerides.
Indian context: Indians tend to have higher triglycerides and lower HDL compared to Western populations even at normal or low BMI — a pattern called dyslipidaemia with normal weight, which makes this test particularly important for the Indian population.
Cost in India: ₹350–₹600
When to retest: At 6 months after starting GLP-1 therapy
Why: GLP-1 medications are generally protective of kidney function in patients with diabetic kidney disease. However, if you already have chronic kidney disease (CKD), dosing and monitoring requirements differ, and some formulations require dose adjustment.
Includes: Serum creatinine, Blood Urea Nitrogen (BUN), estimated GFR (eGFR), uric acid, and electrolytes (sodium, potassium, chloride).
Important red flag: eGFR below 30 mL/min/1.73m² indicates severe kidney impairment — requires specialist endocrinologist or nephrologist consultation before starting GLP-1 therapy.
Cost in India: ₹350–₹700
When to retest: Every 6 months if baseline eGFR is below 60
Why: GLP-1 medications significantly reduce liver fat (non-alcoholic fatty liver disease / hepatic steatosis), which affects an estimated 38% of urban Indians according to a 2023 study in the Journal of Hepatology. A baseline LFT helps track this benefit — and also identifies anyone with existing liver disease where caution is needed.
Includes: SGPT (ALT), SGOT (AST), total bilirubin, direct bilirubin, albumin, total protein, ALP, and GGT.
What to look for: SGPT/ALT more than 3× the upper limit of normal may indicate active liver disease that needs evaluation before starting any new medication.
Cost in India: ₹350–₹600
When to retest: At 6 months after starting
Why: Semaglutide carries an important warning regarding medullary thyroid carcinoma (MTC). While rare, this cancer is associated with GLP-1 receptor activation in animal studies. A baseline TSH also rules out pre-existing hypothyroidism or hyperthyroidism, which can affect weight, metabolism, and symptoms that might otherwise be attributed to GLP-1 therapy.
Important contraindication: GLP-1 medications are contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2). Always inform your doctor of any family history of thyroid cancer.
Cost in India: ₹180–₹350 (TSH alone), ₹400–₹700 (full TFT including T3, T4, TSH)
When to retest: Annually if normal at baseline
Why: GLP-1 can cause nausea, vomiting, and significantly reduced appetite, which over time can contribute to mild nutritional deficiencies or anaemia in vulnerable individuals. A baseline CBC establishes your starting haemoglobin and platelet counts.
Includes: Haemoglobin, RBC count, WBC count, platelet count, MCV, MCH, and differential count.
Cost in India: ₹150–₹300
Why: GLP-1 medications carry a small but documented risk of pancreatitis. This is not common, but if you have a history of gallstones, heavy alcohol use, high triglycerides (above 500 mg/dL), or previous pancreatitis, a baseline amylase and lipase is prudent.
Cost in India: ₹300–₹500
Note: Not required for every patient — discuss with your doctor based on your risk factors
Why: This urine test detects early kidney damage (diabetic nephropathy) before it appears in blood tests. Particularly important if you have diabetes, hypertension, or a family history of kidney disease. GLP-1 medications have been shown to reduce urinary albumin excretion, so a baseline measurement lets you track this kidney-protective benefit.
Cost in India: ₹200–₹400
Why: Scale weight tells you how much you weigh in total, but not how much is fat versus muscle. GLP-1 medications cause both fat loss and some degree of muscle loss. A baseline body composition measurement allows you to track whether you are successfully preserving lean muscle through adequate protein and exercise.
Options:
| Lab | Package Name | Approx. Cost | Key Tests Included |
|---|---|---|---|
| Dr Lal PathLabs | Aarogyam 1.3 | ₹1,599 | CBC, FBG, HbA1c, lipids, LFT, KFT, TFT, Vitamin D, B12 |
| Thyrocare | Aarogyam C | ₹1,850 | Comprehensive metabolic panel including most tests above |
| Metropolis | Wellness Comprehensive | ₹2,100 | Similar comprehensive coverage |
| Apollo Diagnostics | Preventive Health Check | ₹2,499 | CBC, HbA1c, lipids, LFT, KFT, TFT |
Prices as of April 2026. Compare on platforms like NirogStreet, 1mg Labs, or Practo for best deals and home collection options.
| Timepoint | Tests to Get |
|---|---|
| Before starting GLP-1 | All 9 tests listed above — comprehensive baseline |
| 8 weeks after starting | HbA1c, FBG (check early treatment response) |
| 3 months | HbA1c, lipid profile, body weight + composition if possible |
| 6 months | Full repeat panel — LFT, KFT, lipids, HbA1c, CBC |
| Annually | Complete repeat of all baseline tests |
Seek specialist consultation before starting GLP-1 if any of these apply:
Q: Can I get these tests without a doctor's prescription in India? A: Yes, most Indian labs — including Dr Lal PathLabs, Thyrocare, and Metropolis — allow self-referral walk-in or home collection testing without a prescription. However, having a doctor review the results and explain what they mean for your specific situation is strongly recommended.
Q: My doctor said I only need HbA1c before starting. Is that sufficient? A: HbA1c is the minimum monitoring test for diabetes management. However, a comprehensive baseline is better clinical practice when starting a new medication class. You can request a broader panel — most doctors will support this if you ask.
Q: Does Indian health insurance cover these diagnostic tests? A: Most Indian health insurance policies include some preventive health check-up benefits or OPD cover that can be used for diagnostic tests. Check your policy document for 'wellness benefits,' 'OPD coverage,' or 'preventive health check.' Corporate group health insurance often includes an annual health check.
Q: I am getting GLP-1 medication for weight loss only, not diabetes. Do I still need all these tests? A: Yes. GLP-1 medications affect multiple organ systems regardless of why you are taking them. Kidney function, liver health, and thyroid status are all relevant. A comprehensive baseline is important whether you have diabetes or not.
Consult your healthcare provider before starting any medication. This article is a general educational guide and individual requirements will vary based on personal health history, current medications, existing conditions, and other factors. A qualified endocrinologist or physician can review your results and guide your treatment plan.
